1230-P: Patient-Reported Outcomes (PROs) to Treatment in Type 2 Diabetes (T2D) from the International Diabetes Management Practices Study (IDMPS)

Introduction: Treatment acceptance and self-management are essential for achieving better HbA1c in people with diabetes. Methods: IDMPS is an international, observational study investigating care practices and clinical profiles of people with diabetes in developing countries. This analysis of Wave 8 evaluated PROs in people with T2D and their associations with glycemic control using 1) the chronic treatment acceptance questionnaire (ACCEPT) to assess acceptance of long-term medication advantages/disadvantages, and 2) the diabetes self-management questionnaire (DSMQ) to assess health-related behaviors. Results: Of 2475 people with T2D (mean ± SD age 58 ± 12 years, 51% women, diabetes duration ± 8 years, BMI 31 ± 6 kg/m2, HbA1c 8.0 ± 1.8 %, 43% on insulin, HbA1c <7 % 31%) from 13 countries, most completed ACCEPT (99%) and DSMQ (99%) . Acceptance was high for medication effectiveness and side effects, but low for number of medications and their duration (Figure A) . Scores for self-management were low, especially physical activity (Figure B) . Multivariate analyses did not show association of HbA1c <7 % with higher ACCEPT scores (bar effectiveness score) , regardless of treatment. Conclusions: Despite high medication acceptance in developing countries, low self-management calls for further education to improve medication effectiveness. Disclosure P.Aschner: Advisory Panel; Merck & Co., Inc., Sanofi, Speaker's Bureau; AstraZeneca, Boehringer Ingelheim International GmbH, Novo Nordisk. J.C.Chan: Board Member; Asia Diabetes Foundation, Consultant; Bayer AG, Boehringer Ingelheim International GmbH, Celltrion, Merck Sharp & Dohme Corp., Roche Diabetes Care, Viatris Inc., Research Support; Applied Therapeutics, AstraZeneca, Eli Lilly and Company, Hua Medicine, Servier Laboratories, Stock/Shareholder; GemVCare Ltd. J.J.Gagliardino: None. H.M.Ilkova: Advisory Panel; Novo Nordisk. A.Ramachandran: None. J.Mbanya: Advisory Panel; Novo Nordisk, Sanofi, Servier Laboratories. M.V.Shestakova: None. V.Pilorget: None. L.Melas-melt: None. J.Chantelot: Employee; Sanofi, Stock/Shareholder; Sanofi. Funding Sanofi